Werewolf Therapeutics annual current ratio
2020
2021
2022
2023
2024
2025
Werewolf Therapeutics Current Ratio Growth & History (HOWL)
Werewolf Therapeutics's current ratio was 1.62 for fiscal 2025.
View full Werewolf Therapeutics company overviewWerewolf Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.62 | −5.83 | −78.24% |
| 2024 | 2024-12-31 | 7.45 | 0.31 | +4.31% |
| 2023 | 2023-12-31 | 7.14 | 1.30 | +22.18% |
| 2022 | 2022-12-31 | 5.84 | −7.72 | −56.92% |
| 2021 | 2021-12-31 | 13.56 | −4.02 | −22.86% |
| 2020 | 2020-12-31 | 17.58 | — | — |
Werewolf Therapeutics quarterly current ratio
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 2.91 | −2.39 | −45.09% |
| Q1 2026 | 2026-03-31 | 1.27 | −6.83 | −84.37% |
| Q4 2025 | 2025-12-31 | 1.62 | −5.83 | −78.24% |
| Q3 2025 | 2025-09-30 | 3.87 | −6.22 | −61.64% |
| Q2 2025 | 2025-06-30 | 5.30 | −6.83 | −56.29% |
| Q1 2025 | 2025-03-31 | 8.09 | 1.39 | +20.69% |
| Q4 2024 | 2024-12-31 | 7.45 | 0.31 | +4.31% |
| Q3 2024 | 2024-09-30 | 10.10 | 0.45 | +4.68% |
| Q2 2024 | 2024-06-30 | 12.13 | 2.31 | +23.49% |
| Q1 2024 | 2024-03-31 | 6.71 | −0.50 | −6.94% |
| Q4 2023 | 2023-12-31 | 7.14 | 1.30 | +22.18% |
| Q3 2023 | 2023-09-30 | 9.64 | 4.19 | +76.87% |
| Q2 2023 | 2023-06-30 | 9.82 | 4.75 | +93.49% |
| Q1 2023 | 2023-03-31 | 7.21 | −5.98 | −45.35% |
| Q4 2022 | 2022-12-31 | 5.84 | −7.72 | −56.92% |
| Q3 2022 | 2022-09-30 | 5.45 | −16.98 | −75.69% |
| Q2 2022 | 2022-06-30 | 5.08 | −20.21 | −79.92% |
| Q1 2022 | 2022-03-31 | 13.19 | −2.50 | −15.95% |
| Q4 2021 | 2021-12-31 | 13.56 | −4.02 | −22.86% |
| Q3 2021 | 2021-09-30 | 22.43 | — | — |
| Q2 2021 | 2021-06-30 | 25.29 | — | — |
| Q1 2021 | 2021-03-31 | 15.69 | — | — |
| Q4 2020 | 2020-12-31 | 17.58 | — | — |
Werewolf Therapeutics current ratio trends
Over the last five fiscal years, Werewolf Therapeutics's current ratio decreased from 17.58 to 1.62, a change of −15.96. The latest reported quarter, Q2 2026, shows 2.91.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Werewolf Therapeutics source filings ↗